Exelixis

Shrug Off the Market and Consider Exelixis

Yesterday the FDA granted Exelixis (EXEL) a breakthrough designation for their wholly owned drug compound cabozantinib.  The compound will be a a potential treatment for advanced renal cell carcinoma.  The NIH reports approximately 60,000 new cases of renal cancer a year and 14,000 deaths from the disease.Currently there are two drugs on the market right now that treat Pfizer’s (PFE) Inlyta and …

Read more.

Seres Therapeutics CEO: Banking On Bacteria
---
Seres gets orphan drug status

Seres gets orphan drug status

CAMBRIDGE, Mass., Aug 21, 2015 (BUSINESS WIRE) -- Seres Therapeutics, Inc. MCRB, +2.06% a leading microbiome therapeutics platform company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SER-109, an oral therapeutic currently in a Phase 2 clinical trial for the prevention of recurrent Clostridium difficile infection (CDI) in adults. SER-109 is being …

Read more.